<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147277</url>
  </required_header>
  <id_info>
    <org_study_id>900AD</org_study_id>
    <nct_id>NCT00147277</nct_id>
  </id_info>
  <brief_title>ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy</brief_title>
  <acronym>ADVANCE_D</acronym>
  <official_title>ADVANCE-D: ATP Delivery for Painless ICD Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate and quantify the difference in efficacy of two
      sequences of ATP therapies (burst 15 pulses, 88% versus burst 8 pulses, 88%) during an
      episode of spontaneous rhythms classified as fast ventricular tachycardia (FVT) via
      ventricular fibrillation (VF) in patients who have a Class I or II A indication for ICD
      implantation, and thus to promote the &quot;painless&quot; therapy aspect of ICD treatment and improve
      quality of life outcomes for patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective: Compare &amp; quantify efficacy of two different sequences of burst ATP
      strategies for the termination of ventricular tachycardia (with Cycle Lenght (CL) of
      240ms-320ms) from baseline to 12 months post randomisation in patients who are treated with
      ATP -8 pulses, 88% versus patients who are treated with ATP -15 pulses, 88%

      Secondary objectives:

        -  Estimate the efficacy of ATP in successfully treating FVT episodes for patients in
           primary and secondary prevention

        -  Estimate acceleration rate or degeneration of ATP therapy for treating spontaneous FVT
           episodes in the ATP 15 vs 8 arm

        -  Compare the likelihood of syncopal events associated with spontaneous FVT episodes

        -  Estimate the percent reduction in number of shocks delivered per patient for treating
           spontaneous FVT episodes

        -  Evaluate different possible predictors of ATP success: VT rate, underlying disease,
           Anti-Arrhythmic Drugs (AAD), infarct zone, etc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Anti Tachycardia Pacing (ATP) Therapy to Terminate Fast Ventricular Tachycardia (With Cycle Length of 240ms-320msec)</measure>
    <time_frame>one year</time_frame>
    <description>Termination of Ventricular Tachycardia is calculated as percentage of successfully terminated episodes, adjusted for multiple events with (GEE) method. This technique yields an average therapy efficacy and 95% CI that is based on number of patients, number of episodes per patient, and magnitude of the correlation between responses within patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ATP in Successfully Treating FVT for Patients in Primary and Secondary Prevention</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceleration Rate or Degenerated Into VF of ATP for Treating FVT in the 2 Arms</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction in Shocks Delivered Per Patient for Treating FVT</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Likelihood of Syncopal Events Associated With FVT</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Different Possible Predictors of ATP Success</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">925</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>8 pulses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 pulses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardiac Defibrillator</intervention_name>
    <description>Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone</description>
    <arm_group_label>8 pulses</arm_group_label>
    <arm_group_label>15 pulses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICD indications (Class I-II A) according to the guidelines (patient with coronary
             artery disease [CAD] or non-CAD in primary or secondary ICD prevention)

          -  Patients have been implanted with a Medtronic Marquis family ICD capable of ATP for
             FVT via VF

        Exclusion Criteria:

          -  Patient's life expectancy less than 1 year due to a non-cardiac chronic disease

          -  Patient on heart transplant list which is expected in &lt; 1 year

          -  Patient's age less than 18 years

          -  ICD replacements and upgrading (single chamber [SC] ICD® dual chamber [DC] ICD)

          -  Unwillingness or inability to provide written informed consent

          -  Enrollment in, or intention to participate in, another clinical study during the
             course of this study

          -  Inaccessibility for follow-up at the study center

          -  Ventricular tachyarrhythmias associated with reversible causes

          -  Brugada syndrome, long QT and hypertrophic cardiomyopathy (HCM) patients

          -  Other electrical implantable devices (neurostimulators, etc.)

          -  Mechanical tricuspid valve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Lunati, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Niguarda Cà Granda - Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riccardo Cappato, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Policlinico S. Donato Milanese</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Santini, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Filippo Neri - Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angel Arenal, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gregorio Marañón - Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josè Luis Merino, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arcadio Garcia-Alberola, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johann Mermi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic Center Dortmund</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Defaye, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medtronic Italia SpA</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>MI</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lunati M, Defaye P, Mermi J, Garcia-Alberola A, Merino JL, Arenal A, Cappato R, Navarro X, Passardi M, Santini M. Improvement of quality of life by means of antitachy pacing: from PainFREE to the ADVANCE-D Trial. Pacing Clin Electrophysiol. 2006 Dec;29 Suppl 2:S35-9. Review.</citation>
    <PMID>17169131</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>November 20, 2008</results_first_submitted>
  <results_first_submitted_qc>March 25, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2009</results_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <keyword>ATP</keyword>
  <keyword>Thachy</keyword>
  <keyword>FVT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>8 Pulses Anti-Tachycardia Pacing (ATP)</title>
          <description>8 pulses ATP delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)</description>
        </group>
        <group group_id="P2">
          <title>15 Pulses Anti-Tachycardia Pacing (ATP)</title>
          <description>15 pulses ATP delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
                <participants group_id="P2" count="450"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
                <participants group_id="P2" count="450"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>8 Pulses Anti-Tachycardia Pacing (ATP)</title>
          <description>8 pulses ATP delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)</description>
        </group>
        <group group_id="B2">
          <title>15 Pulses Anti-Tachycardia Pacing (ATP)</title>
          <description>15 pulses ATP delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="475"/>
            <count group_id="B2" value="450"/>
            <count group_id="B3" value="925"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="10.9"/>
                    <measurement group_id="B2" value="63.4" spread="12.2"/>
                    <measurement group_id="B3" value="63.7" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="409"/>
                    <measurement group_id="B2" value="402"/>
                    <measurement group_id="B3" value="811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Anti Tachycardia Pacing (ATP) Therapy to Terminate Fast Ventricular Tachycardia (With Cycle Length of 240ms-320msec)</title>
        <description>Termination of Ventricular Tachycardia is calculated as percentage of successfully terminated episodes, adjusted for multiple events with (GEE) method. This technique yields an average therapy efficacy and 95% CI that is based on number of patients, number of episodes per patient, and magnitude of the correlation between responses within patients.</description>
        <time_frame>one year</time_frame>
        <population>934 patients were created in the electronic data capture system, only 925 patients were enrolled in the study: 4 patients in the 8 pulses arm and 5 patients in the 15 pulses arm were created by mistake and excluded from analysis. The analysis were performed with the Intention To Treat (ITT) method.</population>
        <group_list>
          <group group_id="O1">
            <title>8 Pulses Anti-Tachycardia Pacing (ATP)</title>
            <description>8 pulses ATP delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)</description>
          </group>
          <group group_id="O2">
            <title>15 Pulses Anti-Tachycardia Pacing (ATP)</title>
            <description>15 pulses ATP delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Anti Tachycardia Pacing (ATP) Therapy to Terminate Fast Ventricular Tachycardia (With Cycle Length of 240ms-320msec)</title>
          <description>Termination of Ventricular Tachycardia is calculated as percentage of successfully terminated episodes, adjusted for multiple events with (GEE) method. This technique yields an average therapy efficacy and 95% CI that is based on number of patients, number of episodes per patient, and magnitude of the correlation between responses within patients.</description>
          <population>934 patients were created in the electronic data capture system, only 925 patients were enrolled in the study: 4 patients in the 8 pulses arm and 5 patients in the 15 pulses arm were created by mistake and excluded from analysis. The analysis were performed with the Intention To Treat (ITT) method.</population>
          <units>Percentage of FVT episodes terminated</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9"/>
                    <measurement group_id="O2" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of ATP in Successfully Treating FVT for Patients in Primary and Secondary Prevention</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acceleration Rate or Degenerated Into VF of ATP for Treating FVT in the 2 Arms</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction in Shocks Delivered Per Patient for Treating FVT</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Likelihood of Syncopal Events Associated With FVT</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Different Possible Predictors of ATP Success</title>
        <time_frame>one year</time_frame>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura Manotta</name_or_title>
      <organization>Medtronic Italia S.p.A.</organization>
      <phone>003902241371</phone>
      <email>laura.manotta@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

